Oncology Drugs - Niger | Statista Market Forecast

The Oncology Drugs market in Niger is expected to witness substantial growth in the coming years.
According to projections, the revenue in this market is expected to reach US$18.74m in 2024.
Furthermore, it is anticipated that there will be a steady annual growth rate of 7.96% from 2024 to 2029.
As a result, the market volume is expected to reach US$27.49m by 2029.
When compared to the global market, United States is expected to generate the highest revenue, with an estimated value of US$103.90bn in 2024.
Niger's oncology drug market is experiencing a surge in demand due to the increasing prevalence of cancer cases in the country.

Definition:
The Oncology Drugs market covers drugs to treat cancer, including chemotherapy and immunotherapy. These therapies are used for solid tumors and hematologic cancer. The medications in this market are mainly physician-administered drugs.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol-Myers Squibb, Roche, Merck & Co, Novartis, Johnson & Johnson

Treatment for different types of cancer, including skin cancer, leukemia, lymphoma, and multiple myeloma
Chemotherapeutic agents
Immuno-oncology drugs
Oncology orphan drugs

Radiation therapy
Medical devices

The Oncology Drugs market in Niger has been steadily growing over the past few years.

Customer preferences: Niger has a relatively young population, with over 60% of its citizens under the age of 25. This demographic shift has led to an increase in cancer cases, particularly in breast, cervical, and prostate cancers. As a result, there is a growing demand for oncology drugs in the country.

Trends in the market: The market for oncology drugs in Niger is primarily driven by the government's efforts to improve cancer care in the country. The government has taken steps to increase the availability of cancer drugs and to improve cancer screening and diagnosis. This has led to an increase in the number of cancer patients seeking treatment, and consequently, an increase in demand for oncology drugs.

Local special circumstances: One of the major challenges facing the oncology drugs market in Niger is the lack of infrastructure and resources. Niger is one of the poorest countries in the world, and the healthcare system is severely underfunded. This has led to a shortage of medical personnel, equipment, and medicines, including oncology drugs. Additionally, there is a lack of awareness and education about cancer in the country, which has resulted in many cases being diagnosed at a late stage.

Underlying macroeconomic factors: Niger's economy is heavily dependent on agriculture, and the country has been facing recurring food crises due to droughts and floods. This has led to a high level of poverty and malnutrition, which in turn has contributed to an increase in the incidence of cancer. The government has been working to diversify the economy and reduce its dependence on agriculture, but progress has been slow. The country also faces security challenges, with the presence of terrorist groups in the northern and western regions. This has led to a reduction in foreign investment and a slowdown in economic growth. However, the government has remained committed to improving healthcare in the country, and this has led to some progress in the oncology drugs market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Cancer is one of the leading causes of death worldwide, with lung cancer alone ranked the sixth leading cause of death in 2021. Cancer, also known as malignant tumors and neoplasms, is the result of interactions between personal genetic factors and external agents causing abnormal transformations of cells into tumors over time. As the global population has increased in age, the incidence of new cancer cases has also risen, contributing to a higher number of deaths each year. In 2022, nearly 10 million deaths were caused by cancer worldwide- a number which is expected to reach over 15 million by 2040.